

Notice of Allowability	Application No.	Applicant(s)	
	09/750,022	ISAACS, INDU J.	
	Examiner Chih-Min Kam	Art Unit 1653	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to 1/04/05.
2. The allowed claim(s) is/are 1-51,53-55 and 58-78.
3. The drawings filed on 29 December 2000 are accepted by the Examiner.
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some* c) None of the:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application (PTO-152)
6. Interview Summary (PTO-413),
Paper No./Mail Date 20050323.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

jl

An **Examiner's Amendment** to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Michele Simkin on March 23, 2005.

Examiner's Amendments to the Claims:

Cancel claim 52.

Claim 59 has been amended as follows:

59. (Currently amended) The GLP-2 formulation of claim 21, wherein the GLP-2 receptor antagonist has either (1) an amino acid substitution selected from the group consisting of Asp¹⁵, Phe²², Thr²⁹, Thr³², Asp³³, and combinations thereof; or (2) an amino acid substitution of Ala at position 2 by an amino acid selected from the group consisting of Leu, Cys, Glu, Arg, Trp and PO₃-Tyr, wherein the residue or position for the amino acid substitution is numbered according to a mammalian GLP-2.

The following is an **Examiner's Statement of Reasons for Allowance**: The following references appear to be the closest art to the claimed invention. Knudsen *et al.* (WO 99/43361) teach a pharmaceutical composition comprising a GLP-2 derivative or analog, an isotonic agent such as mannitol, a buffer of histidine or sodium phosphate, a pharmaceutical acceptable carrier, a preservative and a surfactant; Kornfelt *et al.* (U. S. Patent 5,652,216) disclose using stabilizing amount of a pharmaceutically acceptable ampholyte such as glycine, histidine or GlyGly in a pharmaceutical preparation comprising glucagons. However, Knudsen *et al.* either alone or in combination with Kornfelt *et al.* do not teach or suggest a GLP-2 formulation comprising a medically useful amount of GLP2 or an analog thereof, a phosphate buffer, L-histidine for stabilizing the formulation and a bulking agent of mannitol and sucrose. Buhl *et al.* (J. Biol. Chem. 263, 8621-8624 (1988)) teach amino acid sequences of GLP-2 from different species; and Lund *et al.* (J. Biol. Chem. 258, 3280-3284 (1983)) teach nucleotide and corresponding deduced amino acid sequences of cDNA encoding two anglerfish pre-proglucagons, where the GLP-2 sequence in the angler fish pre-proglucagon is different from the mammalian GLP-2. Therefore, the claims are allowable over the art of record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached at 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.


Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Chih-Min Kam, Ph. D.
Patent Examiner

CMK

CMK

March 23, 2005



JON WEBER
SUPERVISORY PATENT EXAMINER